The decisions made at the Greater Manchester Medicines Management Group (GMMMG) and Clinical Effectiveness and Governance Committee (CEG) at their meetings in June 2026 have now been reviewed by the Strategic Commissioning Committee and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary
- Targeted-release budesonide for primary IgA nephropathy – red
- Carbidopa / entacapone / levodopa tablets – Sastravi and Stanek added to formulary as preferred options
- Methylphenidate for narcolepsy – amber
- Dupilumab for severe chronic rhinosinusitis with nasal polyps – red
- Obinutuzumab for lupus nephritis – red
- Discontinued items removed from formulary:
- FreeStyle Libre 3 sensors
- Peanut allergy immunotherapy (Palforzia)
- Sotrovimab for COVID-19
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
- Patient information leaflet for DOAC switch – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
- Updated shared care protocol – lisdexamfetamine for ADHD in children and adolescents – https://gmmmg.nhs.uk/shared-care/gmmmg-approved-shared-care-protocols/
For full details of new and updated pathways, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.